Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a: review decison - October 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders (PDF 74 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

Review decision: June 2009 information

Appendix 1: Proposal comment summary table (PDF 28 KB)

Review proposal: May 2009 information

Review proposal: May 2009, Appendix A - Provisional matrix (PDF 37 KB)

Review decision, October 2007  information

Department of Health (PDF 28 KB)

Royal College of Nursing (PDF 20 KB)

Royal College of Physicians (PDF 11 KB)

NHS Quality Improvement Scotland (PDF 20 KB)

Novartis Pharmaceuticals (PDF 11 KB)

Royal Pharmaceutical Society (PDF 11 KB)

Gilead Sciences (PDF 13 KB)

Royal Pharmaceutical Society (PDF 11 KB)

Royal College of Physicians (PDF 11 KB)

Royal College of Nursing (PDF 20 KB)

Novartis Pharmaceuticals (PDF 11 KB)

NHS Quality Improvement Scotland (PDF 20 KB)

Gilead Sciences (PDF 13 KB)

Department of Health (PDF 28 KB)

Review proposal, July 2007 information

Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a: assessment report (PDF 2.49 MB)

People with chronic hepatitis B to benefit from guidance on new drugs and treatments information

People with chronic hepatitis B to benefit from guidance on new drugs and treatments (PDF 47 KB)

Appendix A

Appendix A - matrix of consultees and commentators (PDF 51 KB)

Appendix 1: Proposal comment summary table (PDF 28 KB)

Final Appraisal Determination: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a information

Final Appraisal Determination: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (PDF 93 KB)

Summary Table of Responses to the ACD: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (PDF 161 KB)

Appraisal Consultation Document: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a information

Evaluation report

Overview (PDF 190 KB)

Consultee and commentator comments on the assessment report

British Association for Sexual Health and HIV (BASHH) (PDF 18 KB)

Gilead Sciences (PDF 221 KB)

MRC Clinical Trials Unit (PDF 33 KB)

Roche Products Limited (PDF 36 KB)

Roche Products Limited (cont) (PDF 173 KB)

Roche Products Limited (cont) (PDF 269 KB)

Royal College of Nursing (PDF 16 KB)

Royal College of Pathologists (PDF 11 KB)

Royal College of Physicians (PDF 45 KB)

Non-manufacturer submissions

Royal College of Nursing (PDF 30 KB)

Royal College of Physicians, The British Association for the study of the Liver, and the British Society of Gastroenterology (joint submission) (PDF 140 KB)

Manufacturer submissions (executive summary only)

Gilead Sciences (PDF 78 KB)

Roche Products Ltd (PDF 45 KB)

Expert written personal statements

Dusheiko (PDF 54 KB)

Thomas (PDF 30 KB)

Final scope (PDF 30 KB)

Summary of consultee and commentator comments of the draft scope (PDF 38 KB)

Summary of consultee and commentator comments on the draft matrix (PDF 15 KB)

Archive: Draft scope (PDF 84 KB)

Archive: Provisional matrix (PDF 28 KB)